Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rapport TherapeuticsRAPP -1.69%14 Equity-to-Asset is 0.95 as of Mar. 2026, which is at its 10-year median of 0.95. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Rapport Therapeutics ranks better than 94% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Rapport Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $471.51 Mil. Rapport Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $497.60 Mil.
Therefore, Rapport Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.95.
The historical rank and industry rank for Rapport Therapeutics's Equity-to-Asset or its related term are showing as below:
RAPP'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.32 Med: 0.95 Max: 0.98
Current: 0.95
During the past 4 years, the highest Equity to Asset Ratio of Rapport Therapeutics was 0.98. The lowest was -0.32. And the median was 0.95.
RAPP's Equity-to-Asset is ranked better than 94% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs RAPP: 0.95
Rapport Therapeutics (NAS:RAPP) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Rapport Therapeutics Equity-to-Asset Related Terms
Rapport Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Rapport Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RAPP vs SION, TYRA, IOVA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Rapport Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapport Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapport Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Rapport Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Rapport Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapport Therapeutics (RAPP) has a Equity-to-Asset of 0.95 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Rapport Therapeutics and its competitors. This is near median its historical median of 0.95. According to the industry distribution chart, Rapport Therapeutics ranks #85 out of 1416 companies in the Biotechnology industry, placing it in the top 6%.
Is Rapport Therapeutics' Equity-to-Asset too high?
Rapport Therapeutics' current Equity-to-Asset of 0.95 is near median its 10-year median of 0.95. The Biotechnology industry median Equity-to-Asset is 0.68. Rapport Therapeutics' value of 0.95 is 39.7% above this industry median. Based on the distribution chart, Rapport Therapeutics ranks #85 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' Equity-to-Asset compare to SION and TYRA?
According to the Biotechnology industry distribution chart, Rapport Therapeutics ranks #85 out of 1416 companies for Equity-to-Asset. This places Rapport Therapeutics in the top 6% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Rapport Therapeutics' value of 0.95 is 39.7% above this benchmark. While the company's 10-year median is 0.95 vs. the industry median of 0.68, Rapport Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rapport Therapeutics's current Equity-to-Asset of 0.95 is 39.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Rapport Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapport Therapeutics's current Equity-to-Asset is 0.95, which is near median its own 10-year median of 0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current Equity-to-Asset of 0.95. The current Equity-to-Asset is 0.95, which is near median its 10-year median of 0.95 and 39.7% above the Biotechnology industry median of 0.68. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current Equity-to-Asset is 0.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score
Get the complete analysis for RAPP
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RAPP has been successfully added to your 
